BD partners with Babson on retail blood testing

By staff writers

February 12, 2020 -- Becton Dickinson (BD) and Babson Diagnostics are expanding their collaborative work to include the development of a new blood collection device that does not involve accessing a vein and is practical for use in the retail pharmacy setting.

The new work will involve pairing BD's small-volume capillary specimen collection device, which was developed using the company's Vacutainer platform, with Babson Diagnostics' investigational automated sample handling and analytical technologies.

According to BD, the device will be usable in a broad range of settings with no need for a phlebotomist, and it will deliver laboratory-quality specimens. The plan is to provide convenient, affordable tests that may be ordered by physicians and patients themselves.

The companies noted that they will run clinical studies in retail pharmacies to support filings in the U.S. and internationally.

"Prior to commercialization, Babson Diagnostics is working with local and national retail pharmacies to validate its technology by conducting clinical studies intended for peer-reviewed publication," they explained in a statement.

CVS Health paves way for genetic testing of cancer patients
CVS Health is launching a program that will facilitate genetic testing for cancer patients at the point of prescribing to guide personalized treatment...
Becton Dickinson files for Onclarity FDA approval in 11 more HPV types
Becton Dickinson has submitted a premarket approval filing with the U.S. Food and Drug Administration (FDA) for its Onclarity test for an expanded number...
Myriad Genetics depression test hits Kroger pharmacies
Myriad Genetics' GeneSight pharmacogenomics test for depression is being introduced in hundreds of Kroger Health U.S. pharmacies, as part of a personalized...

Copyright © 2020

Last Updated np 2/12/2020 4:26:08 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.